(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2011 (01.09.2011)

PCT

(10) International Publication Number
WO 2011/104604 A2

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/IB2011/000344

(22) **International Filing Date**:
22 February 2011 (22.02.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/307,009 23 February 2010 (23.02.2010) US

(71) **Applicant** *(for all designated States except US)*: **GLENMARK PHARMACEUTICALS S.A.** [CH/CH]; Chemin de la Combeta, 5, CH-2300 La Chaux-de-Fonds (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BLEIN, Stanislas** [FR/CH]; Chemin de la Combeta, 5, CH-2300 La Chaux-de-Fonds (CH). **HOU, Samuel** [NZ/CH]; Chemin de la Combeta, 5, CH-2300 La Chaux-de-Fonds (CH). **SKEGRO, Darko** [HR/CH]; Chemin de la Combeta, 5, CH-2300 La Chaux-de-Fonds (CH).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/104604 A2

(54) **Title**: ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES

(57) **Abstract**: The invention relates to antibodies directed to α2β1 integrin and their uses, including humanized anti-alpha 2 (α2) integrin antibodies and methods of treatment with anti-α2integrin antibodies. More specifically the present invention relates to humanized anti-α2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.